RPS14 and myelodysplastic syndrome: The survival of non-5q MDS patients with low RPS14 expression seems to be improved by immune-modulating drugs, thus suggesting that these MDS symptoms may improve in MDS-del(5q) patients being administered lenalidomide [40,41].